Evidence map›Paper›PMID 32790488›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2020

A Geroscience Approach to Preventing Pathologic Consequences of COVID-19.

Yan Dou, Soroosh Fatemi, Martin Darvas, Michael Gale, Warren Ladiges

Open access · greenAbstract read
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Editorial: Resilience And Successful Aging.The journal of nutrition, health & aging · 2022
    Article
  2. Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yan DouDepartment of Comparative Medicine, School of Medicine, University of Washington, Seattle, Washington, USA.
Soroosh FatemiDepartment of Comparative Medicine, School of Medicine, University of Washington, Seattle, Washington, USA.
Martin DarvasDepartment of Pathology, School of Medicine, University of Washington, Seattle, Washington, USA.
Michael GaleCenter for Innate Immunity and Immune Disease, Department of Immunology, School of Medicine, University of Washington, Seattle, Washington, USA.
Warren LadigesDepartment of Comparative Medicine, School of Medicine, University of Washington, Seattle, Washington, USA.
University of Washington · US

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
A geroscience approach for treating Alzheimer's diseaseR01AG067193 · NIA · UNIVERSITY OF WASHINGTON · PI DARVAS, MARTIN C, LADIGES, WARREN C · 2020 to 2024
$4.4M
Mechanisms of hepatic innate immune activation by HCVR01AI127463 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL, ROSEN, HUGO RAMON · 2017 to 2021
$2.8M
NIAID NIH HHS R01 AI127463NIAID NIH HHS U01 AI151698NIAID NIH HHS UM1 AI148684NIA NIH HHS R01 AG067193
6 · The paper itself

Abstract

The essential scope of the coronavirus infectious disease 2019 (COVID-19) pandemic is focused on developing effective treatments and vaccines for acute SARS-CoV-2 infection. There is also a critical need to develop interventions to prevent the complications of COVID-19, which occur with an alarming frequency in older adults. Since severe pathologic effects of infection occur with increasing age, COVID-19 falls under the geroscience concept that all diseases in older adults have a common and major underlying cause of declining function and resilience. Geroscience posits that manipulation of aging will simultaneously delay the appearance or severity of major diseases because they share the same risk factor: aging and the multiple processes involved in aging. Drug combinations that target multiple aging processes and the cytokine networks associated with them would not necessarily limit SARS-CoV-2 infection rates but would prevent severe pathologic consequences of the disease in older adults by maintaining a more youthful-like resilience to infection-related complications. A drug cocktail aimed at controlling cytokine actions would complement current clinical treatments and vaccine effectiveness for COVID-19 and serve as a prototype for future age-related infectious disease pandemics wherein the elderly population is especially vulnerable.

Indexed as

AgingBetacoronavirusCoronavirus InfectionsCOVID-19CytokinesHumansPandemicsPhysical FitnessPneumonia, ViralSARS-CoV-2Cytokinesaging resilienceantiaging drug cocktailCOVID-19 complicationscytokinesgeroscienceinteractive cytokines

Identifiers

PMID32790488
PMCPMC7645979
OpenAlexW3048624386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.